Adamis Receives FDA Approval For 505(b)(2) Naloxone

Company Has Partnered With US WorldMeds To Launch Zimhi In Q1 2022

 
• By Akriti Seth
  
Naloxone
Adamis receives approval for its hybrid naloxone for injection • Source: Alamy

More from Products

More from Generics Bulletin